Evaluation of Small Molecule Neurotrophin Mimetics in Models of Neurodegeneration and Neuroinflammation and Novel Insights into the Regulation of Microglial Function
Year: 2025
Type: dissertation
Abstract: Neurodegenerative and neuroinflammatory diseases are conditions of increasing prevalence and pose a global burden on the healthcare system and society. However, treatment of neurodegenerative diseases presents a difficult task owing to the complex pathophysiology of central nervous system (CNS) disorders, and the limited accessibility of the CNS for pharmacological interventions. Microglia, the resident immune cells of the CNS, exert important functions during development in neuronal and synaptic maturation, and are major contributors to the maintenance of CNS homeostasis. In disease conditions, microglia drive pro-inflammatory responses by secretion of cytokines, pro-inflammatory metabolites, reactive oxygen species (ROS) and nitric oxide (NO), and phagocytose pathogens, dead cells and debris. Recent research has shown that microglia activation does not occur simply as an on/off system, but rather by acquisition of numerous activation states dependent on spatiotemporal cues. Chronic activation of microglia can be detrimental for neuronal health and may impede recovery from neurodegenerative diseases. Therefore, gaining deeper insight into the mechanisms regulating microglial activation is of great importance for development of better therapeutics against neurodegenerative and neuroinflammatory diseases. Previous research has shown that the nerve growth factor (NGF), as well as the neurosteroid dehydroepiandrosterone (DHEA) can modulate neuroinflammation by activation of the tropomyosin receptor kinase A (TRKA) receptor on microglia. In this work, we synthesized a novel C-17-spiro-cyclopropyl DHEA derivative, ENT-A010, and showed that it activates the TRKA receptor and its downstream target AKT. Pre-treatment with ENT-A010 enhanced amyloid β phagocytosis and promoted a protective phenotype in lipopolysaccharide (LPS)-treated microglia. Additionally, pre-treatment with ENT-A010 partially preserved the homeostatic gene signature and ramified morphology of microglia in the hippocampi of LPS treated mice. Thus, we have identified ENT-A010, a novel TRKA ligand with the ability to modulate microglial function, as a molecule of interest for further research advancing therapeutic strategies against neurodegenerative disorders. Innate immune responses require increased energy expenditure coupled with cellular metabolic rewiring. However, the cellular metabolic changes in activated microglia remain relatively poorly understood. Here we studied the cellular metabolic changes in brain microglia in mice under LPS treatment. We observed rewiring of microglia metabolism, featured by an increase in OxPhos and induction of aconitate decarboxylase (ACOD1) and itaconate production. Similarly to macrophages, ACOD1 deficiency increased Interleukin 1 beta (Il-1b) production, while treatment with itaconate reduced Il-1b expression in mouse primary microglia. Moreover, ACOD1 deficiency also enhanced production of argininosuccinate, an intermediate metabolite of arginine biosynthesis, while argininosuccinate pre-treatment in mice exacerbated the LPS-induced pro-inflammatory activation of microglia, suggesting that argininosuccinate functions as a pro-inflammatory metabolite. Concluding, our findings revealed that argininosuccinate accumulation enhanced the pro-inflammatory activation of microglia and thus identified suppression of argininosuccinate accumulation as a novel mechanism by which ACOD1-mediated itaconate production can exert anti-inflammatory effects in microglia.
Author: Yilmaz, Canelif
Institution: Technische Universität Dresden
Language: English
Subfield: Neurology
Field: Neuroscience
Domain: Life Sciences
Open Access status: green
Funder: European Commission
OpenAlex ID: W7113444013
